The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer
- 779 Downloads
Therapeutic approach for patients with metastatic breast cancer (MBC) is still controversial. This study was conducted to assess the efficacy and safety of bevacizumab in combination with docetaxel plus capecitabine as first-line treatment for MBC. The feasibility of bevacizumab maintenance therapy in this setting was also evaluated.
Patients and methods
In this single-arm, multicenter phase II study, patients received bevacizumab 15 mg/kg and docetaxel 60 mg/m2 on day 1, plus capecitabine 900 mg/m2 twice daily on days 1–14 every 21 days. Treatment was administered for up to 6 cycles, then bevacizumab continued until progressive disease. The primary end point was progression-free survival (PFS); secondary end points were tumor response rate, overall survival, and toxicity.
Seventy-nine eligible patients were treated with bevacizumab in combination with docetaxel plus capecitabine. The overall response rate was 61 %, with a complete response rate of 8 % and a median duration of response of 10 months. At a median follow-up of 28 months, the median PFS was 11 months. Fifty-two (65 %) patients received bevacizumab maintenance therapy for a median duration of 7 months (range 1 to 33+). Neutropenia was the most common grade 3–4 toxicity (28.1 % of patients), and two fatal adverse events occurred (septic shock and gastrointestinal perforation).
Bevacizumab in combination with docetaxel and capecitabine demonstrates significant activity and quite acceptable toxicity profile as first-line treatment of MBC. Subsequent maintenance therapy with bevacizumab is feasible for a long period of stable disease. Results deserve confirmation.
KeywordsBevacizumab Capecitabine Docetaxel First-line chemotherapy Metastatic breast cancer Angiogenesis
We thank all of the patients and Institutions involved in this study. The authors also thank Silvio Cavuto and Debora Formisano (S. Maria Nuova Hospital, Reggio Emilia) for statistical analysis. Medical writing assistance was provided by Andrea Bothwell in Science Communications, Springer Healthcare.
Conflict of interest
The authors declared that they have no conflict of interest.
- 1.Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008 (2010) Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer. In. Lyon, FranceGoogle Scholar
- 6.Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N (2009) Single agent versus combination chemotherapy for metastatic breast cancer (ReviewThe). Cochrane Library 2009, Issue 1Google Scholar
- 15.Wolmark N Yothers G O’Connell MJ et al (2009) A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 27:LBA4Google Scholar
- 16.Miller VA, O’Connor P, Soh C et al (2009) A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 27:LBA8002Google Scholar
- 18.National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute 2006Google Scholar
- 19.Miles D, Chan A, Romieu G et al (2008) Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26:LBA1011Google Scholar
- 21.Perez EA (2007) Novel enhanced delivery taxanes: an update. Semin Oncol 34(3):suppl 1–5Google Scholar
- 23.Cancer Folkman J (2005) Principles and practice of oncology. Lippincott, Williams & Wilkins, PhiladelphiaGoogle Scholar
- 25.Robert NJ, Dieras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252–1260PubMedCrossRefGoogle Scholar
- 27.Cacheux W, Boisserie T, Staudacher L, Vignaux O, Dousset B, Soubrane O, Terris B, Mateus C, Chaussade S, Goldwasser F (2008) Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 19:1651–1661CrossRefGoogle Scholar
- 29.A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizumab in Combination With Chemotherapy for Patients With Locally Recurrent or Metastatic Breast cancer After First-line Chemotherapy and Bevacizumab Treatment. ClinicalTrials.gov identifier: NCT01250379Google Scholar
- 30.A Randomized Phase III Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer. ClinicalTrials.gov identifier: NCT01200212Google Scholar